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Main text
Non-Hodgkin a diverse group of malignancies, encom-
passing the common diffuse large B-cell lymphoma 
(DLBCL) to the rarer T-cell lymphomas. Chemoresist-
ance is a major barrier to treatment and the mechanisms 
through which it occurs are incompletely understood 
[1]. Although efforts are made to target frequently dys-
regulated pathways in NHL subtypes, these diseases still 
evolve into aggressive forms resistant even to newer ther-
apies [2].
DEAD box helicase 3, X-linked (DDX3X) is an ATP-
dependent RNA helicase and is involved in multiple 
cancer-related cellular processes, including transcrip-
tional regulation, cell adhesion, signal transduction and 
stemness [3]. It plays tumor suppressive or oncogenic 
roles depending on tumor type, and is implicated in vari-
ous cancer types, including glioma, medulloblastoma, 
squamous cell carcinoma, hepatocellular carcinoma, lung 
and breast cancer [3]. A role for DDX3X in NHL sub-
types remains unclear.
Here, we present our novel findings that DDX3X muta-
tions are associated with poor prognosis in DLBCL. We 
demonstrate that mutation/loss of DDX3X in cell lines 
originated from DLBCL, cuteneous T-cell lymphoma 
(CTCL) and NK-cell/T-cell lymphoma (NKTCL) results 
in increased STAT3/p42/p44 phosphotylation and the 
development of chemoresistance. Intriguingly, DDX3X 
mutated/depleted B- and T-cell lineage NHL cell sub-
types remain sensitive to pharmacological inhibitors of 
STAT3.
Recurrent DDX3X mutations in DLBCL are associated 
with worse clinical outcomes
Navigation through NHL patient samples in the cBio-
Portal [4] database revealed that DDX3X was mutated 
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in 49 out of 1343 (3.6%) DLBCL cases. Moreover, 
available database in the ICGC [5] and the COSMIC 
[6] portals revealed mutations in DDX3X in 63 out 
of 1319 (4.7%) and 160 out of 5160 (3.1%) DLBCL 
cases, respectively. Besides DLBCL, DDX3X was also 
recurently mutated in other NHL subtypes, includ-
ing Burkitt lymphoma (BL) and NKTCL [7]. Alto-
gether, we identified 165 missense, 81 truncating, and 
3 in-frame indel mutational variants in the DDX3X in 
NHL subtypes (Fig. 1A). DLBCL patients with DDX3X 
mutations (14 cases out of 223 from 3 different 
cohorts) had significantly worse median overall sur-
vival (41.13 months) compared to cases with wild-type 
DDX3X (211.07 months) (Fig.  1B). The 5-year overall 
survival of DLBCL patients with DDX3X lesions was 
only 22% compared to 72% (p = 0.021) for patients 
without DDX3X alterations (Fig. 1B). Data availability 
for other end-points, such as progression-free survival 
or event-free survival, was insufficient for a robust 
analysis. Notably, we found several other mutations 
that co-existed in DDX3X mutant DLBCL cases (Table 
S2).
We performed whole exome sequencing and 
detected DDX3X mutations in 4 out of 9 relapsed/
refractory DLBCL patients treated with R-CHOP 
or similar regimens. Five damaging DDX3X muta-
tions were identified (PolyPhen-2 score = 1, Table 
S1) in the catalytic domains - R296C and V375fs*8 in 
the “helicase ATP-binding” and R475C, R475H and 
R534H in the “helicase C-terminal” (Fig.  1C). Tar-
geted sequencing of DDX3X on exons 8–15 in sam-
ples from 158 unselected DLBCL patients showed 
damaging DDX3X variants in 5 subjects (3, 95% con-
fidence interval 1–7%) (Fig.  1C). All the identified 
DDX3X mutations were confirmed somatic and 
occurred in residues that are highly conserved across 
various species. These data indicate that DDX3X 
mutations are important determinants of response to 
chemotherapy in DLBCL.
DDX3X mutation/loss in NHL cell subtypes increases 
resistance to antineoplastic drugs
To determine the functional role of DDX3X mutations 
in drug resistance, we stably expressed mutant DDX3X-
R475C in U2392 cells using CRISPR knock-in technique 
[8] and knocked-down DDX3X in a panel of NHL cell 
lines [DLBCL (U2392, BJAB), BL (Raji,), NKTCL (SNK1, 
SNK6, NKYS), and CTCL (HuT78, MJ, MyLa)] using 
DDX3X-targeted shRNA or siRNA (Fig. S1). Cells were 
treated with  IC50 concentrations (of wild-type cells) of 
commonly used histone deacetylase (HDAC) inhibi-
tors (vorinostat, panobinostat, trichostatin, romidep-
sin), STAT3 inhibitors (stattic, WP1066) or doxorubicin 
and cell viability was analyzed by MTS-based assay. 
We observed significant resistance to doxorubicin in 
DDX3X-mutant/depleted U2932 and BJAB cells and to 
HDAC inhibitors in HuT78 and SNK1 cells (Fig.  1D; 
Fig. S2). Importantly, DDX3X-mutant/depleted NHL 
cell subtypes remained sensitive to pharmacological 
STAT3 inhibition (Fig.  1D), although no synergism of 
drug action was identified in these cell-types as ana-
lyzed by determining “Combination Index” using check-
erboard assay and the CompuSyn software (Fig.  1E). 
These results strongly support the clinical data suggest-
ing that DDX3X mutations cause true chemoresistance 
and worse overall survival, rather than simply being 
surrogate markers in NHL subtypes, including DLBCL, 
NKTCL and CTCL.
(See figure on next page.)
Fig. 1 Mutational landscape of DDX3X, its clinical impact and the effect of DDX3X mutation/loss on proliferation, invasiveness and chemoristance 
in NHL cell subtypes. A A lollipop plot showing mutations in the DDX3X gene in NHL that were identified using cancer-associated genomic 
databases from multiple repositories (cBioPortal, ICGC, COSMIC), published literature and OncoKB. B Kaplan-Meier survival analysis of DLBCL 
patients with or without mutations in the DDX3X gene showing overall survival. Available data in cBioPortal are from three different cohorts - the 
Diffuse Large B cell Lymphoma (DFCI, Nat Med 2018; n = 127), Diffuse Large B-Cell Lymphoma (TCGA, PanCancer Atlas; n = 48), and Lymphoid 
Neoplasm Diffuse Large B-cell Lymphoma (TCGA, Firehose Legacy; n = 48); accessed on 14 September 2021. Patients under the the Diffuse Large B 
cell Lymphoma (DFCI, Nat Med 2018) cohort were treated with R-CHOP like chemotherapy, whereas treatment information for patients under the 
other two cohorts is not available. C A mutational lollipop plot depicting 6 different mutations identified in R/R-DLBCL patients (n = 9) using whole 
exome sequencing and 4 different mutations identified in unselected DLBCL patients (n = 158) using targeted sequencing of exons 8–15. D Point 
mutation in DDX3X (DDX3X-R475C) in U2392 cells was created using CRISPR knock-in technique and DDX3X was depleted in U2392, BJAB HuT78 
and SNK1 cell lines by nucleofecting with specific shRNA or siRNA (WT, wild-type; CTL, control; Mock, non-specific siRNA). These cells were incubated 
with  IC50 concentrations (of WT cells as indicated) of vorinostat, panobinostat, trichostatin, romidepsin, stattic, WP1066, or doxorubicin for 48 h. 
Cell viability was accessed by the MTS-based assay. E Cells, as described in “D”, were treated with a varying combinations of vorinostat and WP1066 
and their effects on cell viability were determined and tabulated in terms of “Combination Index”. F The effect of DDX3X mutation/knockdown on 
cell proliferation rates in U2392, HuT78 and SNK1 cells were determined by measuring cell viability using MTS-based assay at multiple time-points 
up to 1 week. (G) Control or DDX3X-mutant/depleted U2392, HuT78 and SNK1 cells were serum starved and allowed to transmigrate through 
Matrigel towards 10% human serum-enriched medium in the trans-well plates for up to 4 h. Cell migration was automatically quantified using 
impedance-based measurements in real-time by xCELLigence Real Time Cell Analyzer. Data represent 3 independent experiments and values in 
graphs are mean ± SEM. **, p < 0.01 *, p < 0.05; ns, non-significant
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Fig. 1 (See legend on previous page.)
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DDX3X mutation/loss enhances proliferation 
and migratory potential of NHL cell subtypes
DDX3X mutation/depletion in U2932, HuT78 and SNK1 
cells significantly increased their proliferation rates in 
comparison to controls, as determined by MTS-based 
assay over 7 days (Fig.  1F). In contrast, forced overex-
pression of wild-type DDX3X in U2932 and HuT78 cells 
significantly decreased proliferation (Fig. S3). Real-time 
monitoring of cells transmigrating through Matrigel, 
using impedance-based measurements, showed sig-
nificantly increased migratory/invasive potentials of 
DDX3X-mutant/depleted NHL cell subtypes (U2932, 
HuT78 and SNK1) (Fig. 1G). Western immunoblot analy-
sis of DDX3X-mutant/depleted U2932 and HuT78 cells 
detected increased vimentin expression in these cell-types 
(Fig. S4). Overexpression of vimentin has been associated 
with aggressive transformation in lymphoma [9].
DDX3X mutation/loss in NHL sybtype‑derived cells 
increase cyclin‑D1 expression
To further investigate the role of DDX3X in NHL sub-
types, we carried out whole RNA-seq analysis of mutant 
DDX3X-R475C U2392, DDX3X-depleted HuT78 and 
DDX3X-depleted SNK1 cells in comparison to their 
wild-type and identified 451, 1682 and 441 differentially 
expressed genes (DEGs), respectively (Fig. 2A; Table S3-
S5). We next performed gene network analysis using 
IPA® (a web-based application that enables analysis, 
integration, and interpretation of RNA-seq and other 
‘omics’ datasets), DAVID (a biological module-centric 
algorithm that functionally analyzes large gene lists), and 
GSEA (an analytical method that determines whether 
an a priori defined gene sets shows significant differ-
ences between two biological states). This multimodal 
analysis of DEGs showed that DDX3X mutation/loss in 
NHL cells enriched cyclin-D1 and JAK-STAT3 path-
ways (Fig.  2B; Fig. S5; Table S6). Using RT-qPCR and 
Western-immunoblot analysis, we verified that cyclin-
D1 mRNA and protein levels were significantly elevated 
in DDX3X-mutant/depleted U2392 and Raji cells relative 
to control (Fig. 2C,D; Fig. S6). A subset of NHL patients, 
including 2.1% of DLBCL cases, has been found to over-
express cyclin-D1 [10] and the upregulation of cyclin-D1 
has been associated with doxorubicin resistance in gas-
tric cancer [11].
DDX3X mutation/loss in NHL cells enhances STAT3/MAPK 
activation
STAT3 and MAPK are well-studied oncogenes, known 
to inhibit apoptosis and decrease response to cytotoxic 
agents [12]. Western immunoblot analysis of DDX3X-
mutated/depleted cell lines derived from DLBCL 
(U2932), NKTCL (SNK1, SNK2) and CTCL (HuT78, MJ, 
MyLa) showed significantly enhanced expression of phos-
phorylated STAT3 (Fig. 2E). Notably, NKYS cells express 
mutant STAT3 with high levels of baseline activity that 
did not increase further. STAT3 knockdown did not affect 
DDX3X expression levels nor did STAT3 directly interact 
with DDX3X (Fig. S7), suggesting that STAT3 hyperphos-
phorylation is a downstream effect of DDX3X lesions. 
Moreover, DDX3X mutation/depletion in NHL subtypes 
(DLBCL, NKTCL, CTCL) significantly increased the 
phosphorylation of p42/44 MAPK (Fig. 2E). STAT3/p42/
p44 pathways are thus likely to be key mediators of the 
tumorigenic effects of DDX3X mutations in the NHL sub-
types studies. Xenografted mutant DDX3X-R475C U2392 
cells showed comparable sensitivity to the STAT3 inhibi-
tor WP1066 in  vivo in comparison to wild-type U2392 
cells into the NOD.Cg-PrkdcscidIl2rgtm1Wjll mice (Fig. 2F).
Conclusions
Despite being uncommon, the biological effects DDX3X 
mutations/loss in DLBCL and other NHL subtypes 
(NKTCL, CTCL), suggest a worse overall survival. 
Fig. 2 RNA-seq and protein network analysis of DDX3X mutant/depleted NHL cell subtypes and the molecular effect of DDX3X mutation/loss on 
DLBCL, NKTCL and CTCL cell lines. A Volcano plots showing DEGs in DDX3X-R475C mutant U2392, and DDX3X-depleted HuT78 and SNK1 cells (false 
discovery rate < 0.05 and p < 0.05) as analysed by RNA-seq (n = 3 each). Gene Ontology functional mapping of DEGs are shown in the corresponding 
insets. B Molecular interaction networks of DEGs that were identified by RNA-seq analysis of the above DDX3X-mutant/depleted cell lines, as 
predicted by the IPA®. Symbols representing protein types and their predicted relationships are provided in the legends. Solid and dashed lines 
represent direct and indirect interactions, respectively. C The mRNA levels of cyclin-D1 (CCND1) in U2392 cells expressing mutant DDX3X-R475C 
(left panel) or transfected with DDX3X shRNA (right panel) were quantified by RT-qPCR (WT, wild-type; CTL, control). D Cyclin-D1 expression 
levels in U2392 cells expressing mutant DDX3X-R475C (left panel) or transfected with DDX3X shRNA (right panel) were quantified by Western 
immunoblotting. Relative densitometry graphs quantifying cyclin-D1 expression are presented. E Control or DDX3X-mutant/depleted cell lines of 
DLBCL (U2392), NKTCL (SNK1, SNK6, NKYS) and CTCL (HuT78, MJ, MyLa) were analysed by Western immunoblotting to determine phosphorylation 
levels of STAT3 and p42/44. Relative densitometry graphs quantifying the expression levels of indicated proteins are presented. (F) U2392 cells with 
wild-type DDX3X or CRISPR knock-in mutant DDX3X-R475C were subcutaneously injected into NOD.Cg-PrkdcscidIl2rgtm1Wjll mice. Cells were left to 
grow for 3 weeks to develop into tumors. Xenografted mice were then injected (intra-tumoral) with vehicle or WP1066 (40 mg/kg) every 3 days for 
up to Day-58. Tumor volume  (mm2) on each mice was recorded twice/week by caliper measurements and calculated by the modified ellipsoidal 
formula. n = 5 under each group. Data represent at least three experiments and values in graphs are mean ± SEM. ***, p < 0.001; **, p < 0.01; *, 
p < 0.05; ns, non-significant
(See figure on next page.)
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Given the high incidence of DLBCL [13, 14], the abso-
lute number of patients with mutated DDX3X is likely 
to be substantial. Our results also suggest that STAT3 
inhibition may be a rational choice for chemoresistant 
NHL (DLBCL, NKTCL, CTCL) patients with mutated 
DDX3X. The STAT3 inhibitor AZD9150 is currently in 
Fig. 2 (See legend on previous page.)
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phase 1b clinical trial in a subset of patients with heavily 
pre-treated lymphoma [15]. Further studies are needed 
to improve our understanding of the consequences of 
DDX3X mutation/loss, which would help improve risk 
stratification of aggressive NHL subtypes and identify 
new therapeutic options for patients with poor prognosis.
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Additional file 1: Supplementary Fig. 1. RNAi-mediated depletion 
of DDX3X in selected NHL cell lines. The above indicated NHL cell lines 
and primary T-cells were nucleofected with DDX3X siRNA or Mock siRNA 
(control) and incubated for 72 h. Few cell lines were stably transfected 
with DDX3X shRNA or control (CTL) shRNA (as indicated) and were 
induced to knockdown DDX3X. In addition, U2392 cells were induced 
to express mutant DDX3X-R475C using CRISPR knock-in technique. (A) 
Cellular lysates from control and DDX3X-depleted/mutant cells were 
Western immunoblotted for quantifying DDX3X protein expression. Blots 
were re-probed for GAPDH or β-actin as loading control. (B) Relative levels 
of DDX3X mRNA were evaluated using quantitative reverse transcription 
PCR (RT-qPCR). Values in the RT-qPCR bar graphs are mean ± SEM. Results 
represent at least 3 independent experiments. **, p < 0.01. Supplemen‑
tary Fig. 2. Consequence of DDX3X loss on refractoriness of HuT78 cells 
towards the effect of vorinostat. HuT78 cells were nucleofected with 
DDX3X siRNA or Mock siRNA (control) and after 48 h, cells were incubated 
with vorinostat  (IC50). Cells were analyzed using MTS assay for cell 
viability (A) and Annexin-V/PI staining with subsequent flow-cytometry 
for apoptosis (B). Cell lysates were collected and Western immunoblot-
ted for determining the expression levels of DDX3X, cleaved PARP, and 
cleaved caspase 3 (C). Blots were re-probed with anti-GAPDH to confirm 
equal loading. Values are mean ± SEM and results represent at least 3 
independent experiments. **, p < 0.01; ***, p < 0.001; ****, p < 0.0001. 
Supplementary Fig. 3. Effect of DDX3X overexpression on the rate of 
proliferation of CTCL and DLBCL cells. HuT78 and U2392 cells were nucleo-
fected with plasmid containing wild-type DDX3X (DDX3X OE) or vector 
alone. The overexpression of DDX3X in HuT78 (A) and U2392 (B) cells was 
confirmed by Western immunoblotting. Relative densitometry graphs of 
DDX3X in both cell types are shown. (C) The rate of HuT78 cell prolifera-
tion was determined by MTS-based assay, performed in triplicates at 48 h 
and 96 h. (D) The viability of U2392 cells was determined by MTS-based 
assay, performed in triplicates at 48 h. Values are mean ± SEM and results 
represent at least 3 independent experiments. *, p < 0.05; **, p < 0.01. 
Supplementary Fig. 4. Effect of the modulation of DDX3X expression on 
the expression levels of vimentin in CTCL and DLBCL cells. (A) HuT78 cells 
were nucleofected with DDX3X siRNA or Mock siRNA (control) and then 
lysed after 72 h. (B) DDX3X wild-type (WT, control) and CRISPR knock-in 
mutant DDX3X-R475C U2392 cells were lysed. (C) U2392 cells transfected 
with control (CTL) or DDX3X shRNA were lysed. (D) HuT78 cells were 
nucleofected with plasmid containing wild-type DDX3X (DDX3X OE) or 
vector alone and then lysed after 72 h. (E) U2392 cells were nucleofected 
with plasmid containing DDX3X OE or vector alone and then lysed 
after 48 h. All the cellular lysates (as indicated in the figure panels) were 
Western immunoblotted for quantifying the expression levels of vimentin. 
Blots were re-probed for GAPDH as loading control. Data represent at 
least 3 independent experiments. Values are mean ± SEM; **, p < 0.01 *, 
p < 0.05. Supplementary Fig. 5. Gene-set enrichment analysis (GSEA) of 
DDX3X-mutant/depleted DLBCL, CTCL and NKTCL cells. Genomic data 
from DDX3X-R475C mutant U2392 (A), DDX3X-depleted HuT78 (B), and 
DDX3X-depleted SNK1 (C) cells were analyzed by GSEA. Hallmark gene 
sets (H) and oncogenic signature (C6) gene sets were collected from the 
Molecular Signatures Database (MSigDB) to produce the enrichment 
plots. p-values were calculated by 1000-gene-set two-sided permutation 
tests. Supplementary Fig. 6. Upregulation of cyclin-D1 in BL cells upon 
DDX3X depletion. Control and DDX3X-depleted Raji cells (using shRNA#1 
or shRNA#2) were lysed, and cellular lysates were analyzed for the expres-
sion levels of DDX3X and cyclin-D1 by Western immunoblotting. Blots 
were re-probed with anti-β-actin to confirm equal loading. Data represent 
at least 3 independent experiments. Values in the relative densitometry 
graphs are mean ± SEM; *, p < 0.05. Supplementary Fig. 7. Effect of 
DDX3X loss on STAT3 regulation in CTCL cells. (A) HuT78 cells were treated 
with DDX3X siRNA and STAT3 GapmeR. Cellular lysates were collected and 
Western immunoblotted to determine the expression levels pSTAT3(Y705), 
STAT3, DDX3X, and GAPDH (loading control). Relative densitometry graph 
of immunoblots is presented. *, p < 0.01. (B) Cell lysates of HuT78 cells 
were immuno-precipitated (IP) using anti-DDX3X antibody or IgG control. 
Subsequently the immuno-precipitates were resolved on SDS-PAGE and 
subjected to immunoblotting with anti-STAT3 and anti-DDX3X antibodies. 
Data represent at least 3 independent experiments.
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